CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Project Number||pCODR 10214|
|Generic Name||Brentuximab Vedotin|
|Indication||Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD)|
|Funding Request||For the treatment of previously untreated patients with Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD).|
|Review Status||Under Review|
|Pre Noc Submission||No|
|NOC Date||May 2, 2019|
|Manufacturer||Seattle Genetics, Inc.|
|Sponsor||Seattle Genetics, Inc.|
|Submission Date||April 2, 2020|
|Submission Deemed Complete||April 21, 2020|
|Submission Type||New Indication|
|Stakeholder Input Deadline ‡||April 17, 2020|
|Check-point meeting||June 3, 2020|
|pERC Meeting (target date)|
|Initial Recommendation Issued (target date)|
|Feedback Deadline (target date) ‡|
|pERC Reconsideration Meeting (target date)|
|Final Recommendation Issued (target date)|
|Notification to Implement Issued|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.